Home » Topics » Infection » HIV/AIDS

HIV/AIDS
RSS

Gilead files NDA for elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for HIV

Nov. 7, 2014

Gilead Sciences begins phase Ib study of GS-9883

Nov. 5, 2014

Bristol-Myers Squibb reports new HIV integrase inhibitors

Oct. 30, 2014

Bristol-Myers Squibb patents new HIV integrase inhibitors

Oct. 28, 2014

Bristol-Myers Squibb prepares novel agents for HIV infection

Oct. 27, 2014

Potency of a novel NRTI against drug-resistant retroviruses

Oct. 16, 2014

Clinical efficacy and safety of a novel antiretroviral drug for HIV infection

Oct. 7, 2014

Clinical results presented for the novel cell-based anti-HIV therapy, SB-728-T

Oct. 6, 2014

EMA committee recommends approval of Rezolsta, announces darunavir label extensions

Sep. 30, 2014

FDA approves Vitekta

Sep. 29, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 9, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...